188 related articles for article (PubMed ID: 23807774)
21. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
[TBL] [Abstract][Full Text] [Related]
22. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
23. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
[TBL] [Abstract][Full Text] [Related]
24. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization.
Choi J; Lee HE; Kim MA; Jang BG; Lee HS; Kim WH
PLoS One; 2014; 9(11):e111658. PubMed ID: 25364819
[TBL] [Abstract][Full Text] [Related]
25. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
26. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.
Ha SY; Do IG; Lee J; Park SH; Park JO; Kang WK; Choi MG; Lee JH; Bae JM; Kim S; Kim KM; Sohn TS
Ann Surg Oncol; 2014 Apr; 21(4):1099-106. PubMed ID: 24306658
[TBL] [Abstract][Full Text] [Related]
27. Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas.
Projetti F; Mesturoux L; Coulibaly B; Durand K; Chaunavel A; Léobon S; Gadeaud E; Caire F; Bessède JP; Labrousse F
Head Neck; 2015 Nov; 37(11):1563-8. PubMed ID: 24913906
[TBL] [Abstract][Full Text] [Related]
28. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
Dziadziuszko R; Wynes MW; Singh S; Asuncion BR; Ranger-Moore J; Konopa K; Rzyman W; Szostakiewicz B; Jassem J; Hirsch FR
J Thorac Oncol; 2012 Feb; 7(2):340-7. PubMed ID: 22237262
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study.
Erichsen R; Kelsh MA; Oliner KS; Nielsen KB; Frøslev T; Lænkholm AV; Vyberg M; Acquavella J; Sørensen HT
Ann Epidemiol; 2016 Jul; 26(7):500-503. PubMed ID: 27318530
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
[TBL] [Abstract][Full Text] [Related]
31. ADAR expression and copy number variation in patients with advanced gastric cancer.
Behroozi J; Shahbazi S; Bakhtiarizadeh MR; Mahmoodzadeh H
BMC Gastroenterol; 2020 May; 20(1):152. PubMed ID: 32410589
[TBL] [Abstract][Full Text] [Related]
32. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
Yang Y; Wang C; Dai C; Liu X; Li W; Huang M; Zhao X; Ji D; Li J; Guo W
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):547-557. PubMed ID: 33693450
[TBL] [Abstract][Full Text] [Related]
33. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.
Saxby AJ; Nielsen A; Scarlett CJ; Clarkson A; Morey A; Gill A; Smith RC
Am J Surg Pathol; 2005 Sep; 29(9):1125-34. PubMed ID: 16096400
[TBL] [Abstract][Full Text] [Related]
34. Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.
De Herdt MJ; Willems SM; van der Steen B; Noorlag R; Verhoef EI; van Leenders GJ; van Es RJ; KoljenoviÄ S; Baatenburg de Jong RJ; Looijenga LH
Oncotarget; 2016 Mar; 7(11):13167-81. PubMed ID: 26909606
[TBL] [Abstract][Full Text] [Related]
35. MET in gastric cancer--discarding a 10% cutoff rule.
Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma.
Tang C; Gao X; Liu H; Jiang T; Zhai X
Int J Clin Exp Pathol; 2014; 7(8):4782-94. PubMed ID: 25197349
[TBL] [Abstract][Full Text] [Related]
37. Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma.
Koh YW; Hur H; Lee D
Pathol Res Pract; 2016 Feb; 212(2):93-100. PubMed ID: 26719224
[TBL] [Abstract][Full Text] [Related]
38. Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.
Higaki E; Kuwata T; Nagatsuma AK; Nishida Y; Kinoshita T; Aizawa M; Nitta H; Nagino M; Ochiai A
Gastric Cancer; 2016 Jan; 19(1):63-73. PubMed ID: 25487305
[TBL] [Abstract][Full Text] [Related]
39. Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker.
Krieg A; Mersch S; Wolf N; Stoecklein NH; Verde PE; am Esch JS; Heikaus S; Gabbert HE; Knoefel WT; Mahotka C
BMC Cancer; 2013 Aug; 13():384. PubMed ID: 23937794
[TBL] [Abstract][Full Text] [Related]
40. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.
Graziano F; Galluccio N; Lorenzini P; Ruzzo A; Canestrari E; D'Emidio S; Catalano V; Sisti V; Ligorio C; Andreoni F; Rulli E; Di Oto E; Fiorentini G; Zingaretti C; De Nictolis M; Cappuzzo F; Magnani M
J Clin Oncol; 2011 Dec; 29(36):4789-95. PubMed ID: 22042954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
